Clinical Trial Update: A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of CHM-2101, an autologous CDH17 CAR-T therapy, is evaluating safety and early efficacy in neuroendocrine tumors, colorectal cancer, and gastr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Neuroendocrine Tumor

Drugs mentioned

• CHM-2101

Snippet

Sponsor: Chimeric Therapeutics | Conditions: Neuroendocrine Tumors, Colorectal Cancer | Phase 1, Phase 2 | Status: RECRUITING